Figure 4.
Treatment with BsPD-L1xrErbB2 bispecific antibody reduces tumor growth and increase tumor rejections. TUBO tumor cells (5 × 105 cells) were injected subcutaneously into Balb/c wild type mice, and treated with different concentrations of control Ig, anti-ErbB2 mAb (7.16.4), anti-PD-L1 mAb or BsPD-L1xrErbB2 bispecific antibody injected intraperitoneally on days 19, 22, 26 and 29 (a, b) or on days 16, 19, 23 and 26 (c, d). Mice were monitored for tumor growth and results are expressed as mean tumor area ± SEM. (b, d) Data is shown for the percentage of mice rejecting tumors/group (gray bars, tumor-bearing mice; black bars, tumor-free mice for at least 60 d). Arrow represents the day treatment was started. Statistical analysis was performed using two-way ANOVA Turkey’s multiple comparisons test at day 44 for A and day 28 for C (*, P < 0.05; **, P < 0.005; ***, P < 0.0005; ****, P < 0.0001; ns: not significant).